Nelarabine

• CAT Number: A001032
• CAS Number: 121032-29-9
• Molecular Formula: C11H15N5O5
• Molecular Weight: 297.27
• Purity: ≥95%
• Synonyms: 506U78
• Target: Apoptosis
• Solubility: >14.9mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• InChI: InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
• InChIKey: IXOXBSCIXZEQEQ-UHTZMRCNSA-N
• SMILES: COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N

Nelarabine（Cat No.:A001032）is a prodrug of arabinosylguanine (ara-G), a nucleoside analog used in cancer treatment, particularly for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Once metabolized, Nelarabine converts to ara-GTP, which incorporates into DNA, leading to chain termination and apoptosis in rapidly dividing cancer cells. Its specificity for T-lymphocytes makes it an effective treatment option for T-cell malignancies. Nelarabine is typically used in patients who have relapsed or are refractory to other treatments, offering a targeted approach to disrupt DNA synthesis in cancer cells.

Reference

1:Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma. Lalayanni C, Baldoumi E, Papayiannopoulos S, Tziola K, Saloum R, Anagnostopoulos A.Curr Probl Cancer. 2016 Nov 17. pii: S0147-0272(16)30050-2. doi: 10.1016/j.currproblcancer.2016.11.005. [Epub ahead of print] PMID: 28169005
2:Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Kadia TM, Gandhi V.Expert Rev Hematol. 2017 Jan;10(1):1-8. doi: 10.1080/17474086.2017.1262757. Epub 2016 Dec 8. Review. PMID: 27869523
3:Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zambonin L, Neri LM, Martelli AM, Chiarini F.J Hematol Oncol. 2016 Oct 24;9(1):114. PMID: 27776559 Free PMC Article
4:Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma. Sripornsawan P, Okamoto Y, Nishikawa T, Kodama Y, Yamaki Y, Kurauchi K, Tanabe T, Nakagawa S, Shinkoda Y, Imuta N, Kawano Y.Pediatr Blood Cancer. 2017 Feb;64(2):250-253. doi: 10.1002/pbc.26214. Epub 2016 Aug 31. PMID: 27576612
5:Severe, reversible nelarabine-induced neuropathy and myelopathy. Alberti P, Parma M, Pioltelli P, Pogliani EM, Terruzzi E, Stasia A, Doni E, Cecchetti C, Cavaletti G.J Peripher Nerv Syst. 2016 Sep;21(3):154-6. doi: 10.1111/jns.12173. No abstract available. PMID: 27117493
6:MR imaging in nelarabine-induced myelopathy. Dua SG, Jhaveri MD.J Clin Neurosci. 2016 Jul;29:205-6. doi: 10.1016/j.jocn.2015.12.014. Epub 2016 Feb 16. Review. PMID: 26899359
7:Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.Br J Haematol. 2016 Jul;174(2):332-4. doi: 10.1111/bjh.13771. Epub 2015 Sep 25. No abstract available. PMID: 26403537
8:Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease. Nishijima TF, Shea TC, Wood WA, Voorhees PM, Jamieson K.Leuk Lymphoma. 2016;57(4):957-60. doi: 10.3109/10428194.2015.1083096. Epub 2015 Oct 8. No abstract available. PMID: 26293208
9:Nelarabine associated myotoxicity and rhabdomyolysis. Haider M, Rizvi SA, Kasi PM.Case Rep Hematol. 2015;2015:825670. doi: 10.1155/2015/825670. Epub 2015 Mar 18. PMID: 25866685 Free PMC Article
10:Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children/’s Oncology Group Study AALL0434. Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. doi: 10.1002/pbc.25470. Epub 2015 Mar 8. PMID: 25755211 Free PMC Article